Documents
- InDex Pharmaceuticals Holding AB - Annual Report 2017 - 24 April 2018 - Swedish
Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
Click here to read more about us!InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden
InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
Click here to read more about us!InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden
NLS Insight's goal is to assist the Nordic regions leading innovators in targeting business collaborations, parnership opportunities and investment potential.
Designed by Horn Media 2019